An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Elamipretide (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Acronyms ReCLAIM
- Sponsors Stealth BioTherapeutics
- 07 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
- 07 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.
- 14 Nov 2016 Top-line data are expected mid-year 2017, as per a Stealth BioTherapeutics media release.